XML 24 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 13, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Trading Symbol CUE    
Entity Registrant Name Cue Biopharma, Inc.    
Entity Central Index Key 0001645460    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   43,168,468  
Entity Public Float     $ 82.1
Entity Interactive Data Current Yes    
ICFR Auditor Attestation Flag false    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity File Number 001-38327    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 47-3324577    
Entity Address, Address Line One 40 Guest Street    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02135    
City Area Code 617    
Local Phone Number 949-2680    
Document Annual Report true    
Document Transition Report false    
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2022. Portions of such proxy statement are incorporated by reference into Part III of this Form 10-K.

    
Auditor Name RSM US LLP    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 49